


RECEIVED

RECEIVED GROUP 180

SEP 19 1989

SEP 15 1989 Sheet 1 of 3

Form PTO-1449
(REV. 2-83)

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

YALE 204-RSB

SERIAL NO.

06/942,666

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JR	AA	3 8 1 7 9 8 2	6/18/74	Verheyden et al	536	23	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER		DATE	COUNTRY		TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JR	AR	European Search Report
JR	AS	Biochemical and Biophysical Research Communications
JR	AT	pages 128-134 Vol. 142 No. 1, 1987 January 15, 1987 The Anti-Htlv-111(Anti-HIV) and Cytotoxic Activity of 2'-3'-Didehydro-2',3'-dideoxyribonucleosides: A comparison with their Parental 2',3'-Dideoxyribonucleosides Jan Balzarini et al; Mol. Pharmacol. 32 (1) Juli 1981 pages 162-167

EXAMINER

JR

DATE CONSIDERED

18/11/89

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
SEARCHED GROUP 180

SEP 19 1989

SEP 15 1989

2

of 3

Form PTO-1449
(REV. 2-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEMAILED ON SEPTEMBER 15, 1989
AND IN THE MAIL BY SEPTEMBER 15, 1989

SERIAL NO.

06/942,666

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)APPLICANT
Tai-Shun et alFILING DATE
December 17, 1986GROUP
183

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AAR	Inhibition by 2', 3'-Dideoxythymidine or Retroviral infection of Mouse and Human Cells Philip Furmanski et al; Cancer letters 8 (1980) pages 307-315
	14
AAS	Potent and Selective Anti-HIV-III/Lav Activity of 2', 3'-Dideoxycytidinene, The 2', 3'-Unsaturated Derivative of 2', 3'-Dideoxycytidine Jan Balzarini et al; Biochem. Biophys. Res. Commun. pages 735-742 Vol. 140 No. 2 1986
	14
AAT	Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2', 3'-dideoxynucleosides; Hiroaki Mitsuya et al; Vol. 83, pages 1911-1915 March 1986 Proc. Natl. Acad. Sci. U.S.A.
	14

EXAMINER

DATE CONSIDERED


10/11/89

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED RECD GROUP 180

SEP 19 1989

SEP 15 1989 Sheet 3 of 3

Form PTO-1449
(REV. 2-83)PATENT NO.
Value 204-RSBSERIAL NO.
06/942,666APPLICANT
Tai-Shun et alFILING DATE
December 17, 1986GROUP
183

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
AL						
AM						
AN						
AO						
AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AA AR	Synthesis of Uracil and Thymine Nucleosides of Unsaturated 5-(Aminoacyl) Aminopentofuranoses Takeshi Adachi et al; pages 113-124 Carbohydrate Research, 73 (1979)	14
AS		
AT		

EXAMINER

TR Ollie

DATE CONSIDERED

10/11/89

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.